Get started
ABBOTT LABORATORIESAA

ABBOTT LABORATORIES

111.30EURD
+2.08+1.90%
As of today at 08:49 GMT
EUR
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

ABL trade ideas

ABT updateThis is a trade I did enter after my initial post, I was bullish on ABT turning around, and hoping for falling interest rates which did occur. My strategy here was to purchase a LEAP before this breakout. I will hold this and sell covered-calls against it after earnings next week, if we get a large move I will make out heavily. I might decide to keep my LEAP and exercise it in 2026 due to the value I was able to snipe. -My short term target is the dashed green -Medium term 115$ -Next years target > 125$
NLong
by Apollo_21mil
ABT, technical BTD Abbott Laboratories (ABT) recently swept its monthly fair value gap and saw a significant price increase from $102 to $104 on Friday. Despite the jump, there was no specific news driving this above-average ATR daily movement. The stock has been holding above the $100 level, building a solid base, and the chart looks promising. With earnings due on July 18, it's worth monitoring, though no trade will be entered yet. Keep an eye on further developments as the earnings date approaches.
NLong
by thinkCNE
Abbott Laboratories Shows Resilience with Strong Q1 Performance In the dynamic landscape of healthcare, Abbott Laboratories (NYSE: NYSE:ABT ) stands out with its robust first-quarter performance, showcasing resilience and adaptability amidst challenging conditions. Bolstered by a surge in medical device sales and buoyed by promising growth across multiple sectors, Abbott has exceeded expectations and raised its annual guidance, signaling confidence in its trajectory. Let's delve deeper into the factors driving Abbott's success and the implications for investors. 1. Medical Devices Lead the Charge: Abbott's ( NYSE:ABT ) first-quarter success story is largely attributed to the stellar performance of its Medical Devices segment, which witnessed a remarkable organic growth of 14.3%. The star performer within this segment was FreeStyle Libre, demonstrating a phenomenal 23.3% organic growth, underscoring the growing demand for innovative healthcare solutions. 2. Diversification Pays Off: Abbott's diversified portfolio, spanning Established Pharmaceuticals, Nutrition, and Diagnostics, was pivotal in driving overall growth. With double-digit organic growth in Established Pharmaceuticals and substantial gains in Nutrition and Diagnostics, Abbott has showcased its ability to capture opportunities across various healthcare segments. 3. Strategic Innovations: The approval of Abbott's Heart Valve Repair Device by the FDA marks a significant milestone, reinforcing the company's commitment to advancing medical technology. This breakthrough underscores Abbott's relentless pursuit of innovation to address critical healthcare needs, thereby positioning the company for sustained growth and market leadership. 4. Earnings Beat and Guidance Revision: Abbott's impressive adjusted diluted earnings per share of $0.98 not only surpassed analyst estimates but also instilled confidence in the company's financial performance. The upward revision of its fiscal year 2024 adjusted EPS guidance to $4.55-$4.70 reflects management's bullish outlook and underscores Abbott's strong growth prospects in the coming quarters. 5. Market Response and Outlook: Despite the premarket dip in NYSE:ABT shares, Abbott's robust performance and revised guidance signal a compelling investment opportunity. With a solid foundation, innovative pipeline, and optimistic outlook, Abbott is poised to navigate uncertainties and deliver sustainable value to shareholders in the long term.
N
by DEXWireNews
ABT breakout!ABT just broke out of a downtrend while simultaneously battling a key resistance zone. It did so, while gaining positive momentum within a monthly TTM squeeze (and firing the Daily Squeeze). If it can hold above the newly formed support, it might be ready for a bullish run up to its previous all-time-high, which is coincidentally equidistant from the newly formed low. Before it can do that, it needs to fight through resistance within the "golden" fibonacci zone (up to $122). I'll wait for it to break free of this zone before I try to ride it up to the next level and/or the high!
NLong
by ThetaGator
Abbott Laboratories (ABT) Navigating Earnings Abbott Laboratories ( NYSE:ABT ) recently reported earnings that slightly missed expectations at the midpoint, causing a 3.3% dip in NYSE:ABT stock to $110.21. However, a closer look at the results reveals a more nuanced story. Despite the earnings guidance falling short by three pennies at $4.60 per share for the year, the health care giant remains resilient, projecting a robust 8% to 10% organic sales growth. Investors should pay attention as NYSE:ABT stock forms a saucer base with a potential buy point at $115.83. Strong Growth in Medical Devices: One of the key drivers behind Abbott's solid performance was the outstanding growth in its medical devices segment. Sales in this category surged 15.4% organically to $4.44 billion. Notably, the diabetes division played a significant role, with revenues reaching $1.55 billion, marking a substantial 20.7% increase. The star performer in this space was Abbott's body-worn glucose monitor, FreeStyle Libre, which contributed $1.4 billion in sales, up by an impressive 23.8% on an organic basis. Electrophysiology Segment Shines: Another highlight for Abbott ( NYSE:ABT ) was the electrophysiology segment, where revenue grew 15.9% organically to nearly $2.2 billion. This growth is particularly noteworthy considering the challenges posed by a new technology called pulsed field ablation (PFA), which is emerging in the electrophysiology testing space. Analysts believe that Abbott's robust performance in this segment allays fears of losing market share to PFA, underscoring the company's adaptability and resilience. Rapid Diagnostics Faces Headwinds: While Abbott ( NYSE:ABT ) celebrated success in medical devices and electrophysiology, the rapid diagnostics segment faced headwinds. Excluding Covid tests, sales declined by 13.7% to $862 million. The decline was attributed to a later-than-expected flu season, with cases spiking in January. Despite this setback, core lab sales managed to climb 9.7% to $1.37 billion, showcasing the diversified portfolio and the ability to navigate challenges. Conclusion: Abbott Laboratories' ( NYSE:ABT ) recent earnings report might have initially disappointed investors, but a deeper analysis reveals a company that is strategically positioned for growth. With a saucer base forming and a potential buy point at $115.83, savvy investors may see this dip in NYSE:ABT stock as a buying opportunity. Abbott's ability to innovate in the medical devices space, navigate challenges in rapid diagnostics, and shine in electrophysiology suggests that the company is well-poised for sustained success in the dynamic healthcare industry.
N
by DEXWireNews
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t sold the regional top on ABT: Nor reentered this fantastic dip: Then analyzing the options chain and the chart patterns of ABT Abbott Laboratories prior to the earnings report this week, I would consider purchasing the 115usd strike price at the money Calls with an expiration date of 2024-2-16, for a premium of approximately $2.26. The chart is overextended and the RSI overbought, but I think there is one more leg to go before a correction. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
NLong
by TopgOptions
1
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t bought ABT here: or sold it here: Then analyzing the options chain and the chart patterns of ABT Abbott Laboratories prior to the earnings report this week, I would consider purchasing the 91usd strike price Calls with an expiration date of 2023-10-27, for a premium of approximately $3.15. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NLong
by TopgOptions
2
Abott to turnaround at trend line support?Abbott Laboratories - 30d expiry - We look to Buy at 104.11 (stop at 100.91) The trend of higher lows is located at 104. The primary trend remains bullish. This stock has seen good sales growth. 104 continues to hold back the bears. Although the bears are in control, the stalling negative momentum indicates a turnaround is possible. Our profit targets will be 112.11 and 114.11 Resistance: 106.20 / 108.50 / 110.00 Support: 103.28 / 100.38 / 99.30 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group
NLong
by VantageMarkets
ABT - 9 months SYMMETRICAL TRIANGLE══════════════════════════════ Since 2014, my markets approach is to spot trading opportunities based solely on the development of CLASSICAL CHART PATTERNS 🤝Let’s learn and grow together 🤝 ══════════════════════════════ Hello Traders ✌ After a careful consideration I came to the conclusion that: - it is crucial to be quick in alerting you with all the opportunities I spot and often I don't post a good pattern because I don't have the opportunity to write down a proper didactical comment; - since my parameters to identify a Classical Pattern and its scenario are very well defined, many of my comments were and would be redundant; - the information that I think is important is very simple and can easily be understood just by looking at charts; For these reasons and hoping to give you a better help, I decided to write comments only when something very specific or interesting shows up, otherwise all the information is shown on the chart. Thank you all for your support 🔎🔎🔎 ALWAYS REMEMBER "A pattern IS NOT a Pattern until the breakout is completed. Before that moment it is just a bunch of colorful candlesticks on a chart of your watchlist" ═════════════════════════════ ⚠ DISCLAIMER ⚠ The content is The Art Of Charting's personal opinion and it is posted purely for educational purpose and therefore it must not be taken as a direct or indirect investing recommendations or advices. Any action taken upon these information is at your own risk.
NLong
by TheArtOfCharting